Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL4581 Target Snapshot

Kinesin-like protein KIF11 · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
1,258Compounds
184Assays
0Approved Drugs
1,441.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Kinesin-like protein KIF11 shows clinical signal disease relevance led by non-small cell lung carcinoma. 5 more disease programs remain visible in the same review block. 2 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P52732. Start with non-small cell lung carcinoma, then reuse UniProt P52732 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with non-small cell lung carcinoma, then reuse UniProt P52732 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14 2 linked drugs
Open source guide
Disease program
non-small cell lung carcinoma

Kinesin-like protein KIF11 shows clinical signal disease relevance led by non-small cell lung carcinoma. 5 more disease programs remain visible in the same review block. 2 linked drugs remain visible in the same block.

Start review with non-small cell lung carcinoma because it currently carries clinical signal support. Linked drugs include ISPINESIB, LITRONESIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Clinical signal Open Targets-ready proxy 2 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Kinesin-like protein KIF11 as ChEMBL target CHEMBL4581, mapped to UniProt P52732. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Kinesin-like protein KIF11
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL4581
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P52732
Kinesin-like protein KIF11
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Kinesin-like protein KIF11 is the right protein anchor across sources, using UniProt P52732 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why non-small cell lung carcinoma is currently framed as clinical signal support. It currently carries 2 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameKinesin-like protein KIF11
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtP52732
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelKinesin-like protein KIF11
UniProt AccessionP52732
Component TypeProtein
Sequence Length1056 aa

Kinesin-like protein KIF11

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Kinesin-like protein KIF11, mapped to UniProt P52732. Sequence length is 1056 aa.

Mapped IDP52732
Review nameKinesin-like protein KIF11
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Clinical signal Open Targets-ready proxy

Kinesin-like protein KIF11 shows clinical signal disease relevance led by non-small cell lung carcinoma. 5 more disease programs remain visible in the same review block.

Clinical signal Phase II
non-small cell lung carcinoma
2 linked drugs · 2 direct · 2 efficacy
Linked drugISPINESIB
Linked drugLITRONESIB
Clinical signal Phase II
ovarian cancer
2 linked drugs · 2 direct · 2 efficacy
Linked drugISPINESIB
Linked drugLITRONESIB
Clinical signal Phase II
breast cancer
1 linked drug · 1 direct · 1 efficacy
Linked drugLITRONESIB
Clinical signal Phase II
breast neoplasm
1 linked drug · 1 direct · 1 efficacy
Linked drugISPINESIB
Clinical signal Phase II
colorectal cancer
1 linked drug · 1 direct · 1 efficacy
Linked drugLITRONESIB
Clinical signal Phase II
cutaneous melanoma
1 linked drug · 1 direct · 1 efficacy
Linked drugISPINESIB
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with non-small cell lung carcinoma because it currently carries clinical signal support. Linked drugs include ISPINESIB, LITRONESIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasenon-small cell lung carcinoma
Strongest levelClinical signal
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

1
Phase III
5
Phase II
3
Phase I
Assay Mix

Activity Type Distribution

IC501,133.0
KI214.0
EC5084.0
KD10.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL2325429 9.85 IC50 0.14 Preclinical
CHEMBL247044 9.7 IC50 0.2 Preclinical
CHEMBL4239814 9.7 IC50 0.2 Preclinical
CHEMBL5778625 9.57 IC50 0.271 Preclinical
CHEMBL398478 9.4 IC50 0.4 Preclinical
CHEMBL5951006 9.35 IC50 0.446 Preclinical
CHEMBL5842292 9.34 IC50 0.457 Preclinical
CHEMBL5827710 9.33 IC50 0.47 Preclinical
CHEMBL206115 9.3 IC50 0.5 Preclinical
CHEMBL2325429 9.3 Ki 0.5 Preclinical
Distribution

pChEMBL Value Distribution

144
5.0
134
5.5
185
6.0
209
6.5
145
7.0
106
7.5
89
8.0
72
8.5
32
9.0
5
9.5
pChEMBL
Assay Landscape

Assay Landscape

184
Total Assays
990
Tested Compounds
2
Assay Types
Binding — 176 assays, 990 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 107 649 6.7
assay format 45 286 6.7
cell-based format 24 55 6.4
Functional — 8 assays, 73 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 6 53 5.3
cell-based format 2 20 6.9

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine